Improved Biomanufacturing and Downstream Processing of Vaccines and Biopharmaceuticals

The global market for biopharmaceuticals and vaccines in 2019 is expected to reach US$269.3 billion. This multidisciplinary project addresses an important Industrial challenge associated with the manufacturing and downstream processing of vaccines and biopharmaceuticals. This project is in collaboration with the industrial partner Porton Biopharma LTD which are currently the manufacturer of Erwinase and Anthrax vaccine.

In order to meet the growing demand of these products worldwide, significant improvements in the manufacturing processes are needed. Current manufacturing processes are lengthy and involve many different steps. This projects aims to develop novel methods to improve current biomanufacturing and downstream processing of these important products, including the generation of novel high affinity nucleic acid ligands (aptamers) to Erwinase and Anthrax vaccine. In addition, this project aims to develop novel bioanalytical methods for the detection, purification, identification and quantification of important biopharmaceuticals and vaccines including Erwinase and Anthrax vaccine.